HALO logo
halo search icon
PER
Percheron Therapeutics Limited

PER · Percheron Therapeutics Limited

0.003

AUD
-0.001 (-25.00%)
11/08/2026 04:10:10 PM
+1
Price change (7D)

Unlock stock Insights

Create a free account to unlock price targets, recommendations, and commentary.

Overview

Market Cap

AU$6.09M

PE

0.00

EV/EBITDA

N/A

DIV Yield

0%

Franking

0%

MQV Rating

5Very Weak

As at 11/08/2026 04:10:10 PM

Price Chart

Description

Percheron Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. It operates through the ATL1102, and ATL1103 segments. The ATL1102 segment represents the second generation antisense inhibitor of CD49d, the alpha subunit of very late antigen-four. The ATL1103 segment refers to atesidorsen is an antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin. The company was founded on November 13, 2000 and is headquartered in Toorak, Australia.

  • All-Companies
  • All-Consensus
  • Big Candle
  • GROWTH AUS
  • HALO Consensus Value
  • HALO Growth
  • HALO Ords

Key Fundamentals

EPS 3 yr Growth

59.60%

EBITDA Margin

N/A

Operating Cashflow

-$16m

Free Cash Flow Return

-161.50%

ROIC

-154.10%

Interest Coverage

NaN

Quick Ratio

5.10

Performance

52 weeks range

Low 0 - 0.01

Trade Value (12mth)

AU$3,084.00

1 week

33.33%

1 month

14.29%

YTD

-56.77%

1 year

-48.67%

All time high

1.80

Additional Data

Shares Outstanding (Fully Diluted)

1,116m

HALO Sector

Healthcare

Next Company Report Date

02-Sep-26

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

Consensus

Lock Icon

Unlock full consensus

Consensus score

Lock Icon/10

Recommendation

Buy

Target price

Lock Icon

Deviation

Lock Icon

Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Momentum

Price

Strong

Earnings

Strong

Growth

Earnings

Very Strong

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

Valuation

Lock Icon

Unlock full dataset

Value

Lock Icon

Consensus

Lock Icon

Yield

Lock Icon

News & Announcements

DateEvent
10 August 26ASXD
31 July 26ASXD
03 July 26ASXD
17 June 26ASXD
02 June 26ASXD

See beyond the curve.

One solution for research, investing and portfolio management.
Start FREE Trial
Want to learn more?Frequently asked questions.
1
What is the current share price of Percheron Therapeutics Limited (PER:ASX)?
Halo FAQ
The current share price of Percheron Therapeutics Limited (PER:ASX) is AUD$0.00.
2
What is the 52-week high share price for Percheron Therapeutics Limited (PER:ASX)?
Halo FAQ
The 52-week high share price for Percheron Therapeutics Limited (PER:ASX) is AUD$0.01.
3
What is the 52-week low share price for Percheron Therapeutics Limited (PER:ASX)?
Halo FAQ
The 52-week low share price for Percheron Therapeutics Limited (PER:ASX) is AUD$0.00.
4
What is the dividend yield for Percheron Therapeutics Limited (PER:ASX)?
Halo FAQ
Percheron Therapeutics Limited (PER:ASX) does not pay a dividend.
5
What was Percheron Therapeutics Limited (PER:ASX) last dividend payment?
Halo FAQ
Percheron Therapeutics Limited (PER:ASX) does not pay a dividend.
6
What is the franking level for Percheron Therapeutics Limited (PER:ASX)?
Halo FAQ
Percheron Therapeutics Limited (PER:ASX) has a franking level of 0.00%.
7
In which sector is Percheron Therapeutics Limited (PER:ASX) classified?
Halo FAQ
Percheron Therapeutics Limited (PER:ASX) is classified in the Healthcare.